| Profiles RNS

Profile

MD, George Washington University
BS, Duke University

Websites

	Pulmonary, Allergy, Sleep & Critical Care Medicine Faculty
	Boston Medical Center Physician Provider Profile
	BU Scleroderma Center of Research Translation

ORCID : 0000-0002-0297-7902

BU Research
NIH RePORTER Research

A 24-Week Pilot Study to Investigate Changes in Proteomic and Genomic Profiles in Patients with Pulmonary Arterial Hypertension Associated with Scleroderma Treated with Macitentan-PIONEER 2
11/05/2015 - 11/04/2024 (PI)
Actelion Pharmaceuticals, Ltd.

A Phase 2, Dose-ranging, Randomized, Double-blind, Placebo Controlled Study of GS-4997 in subjects with Pulmonary Arterial Hypertension
12/22/2014 - 12/21/2021 (PI)
Gilead Sciences, Inc.

A Phase IV, Prospective, Single-Arm, Open-Label Study to measure Outcomes in Patients with Pulmonary Arterial Hypertension not on active treatment
02/25/2015 - 02/24/2020 (PI)
Bayer HealthCare Pharmaceuticals

REPAIR: Right Ventricular Remodeling in Pulmonary Arterial Hypertension
07/15/2015 - 07/14/2019 (PI)
Actelion Pharmaceuticals, Ltd.

Uptravi® (SelexiPag): tHe usErs dRug rEgistry
09/01/2016 - 08/31/2018 (PI)
Actelion Pharmaceuticals US, Inc.

A Prospective, multicenter, double-blind, randomized, placebo-controlled, parallel-group, 12-week study to evaluate the safety and tolerability of macitentan in subjects with combined pre- and post-ca
06/11/2014 - 06/06/2018 (PI)
Actelion Clinical Operations, Inc.

NIAMS: CORT
09/01/2011 - 08/31/2017 (Sub-Project Level Key Person)
PI: Robert W. Simms, MD
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases
5P50AR060780-05

A Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled, Nitric Oxide (iNO) Versus Placebo as Add-On Therapy in Sympto
06/01/2012 - 05/31/2017 (PI)
Ikaria

A multi-Center, Double Blind, Placebo-Controlled Phase 3 Study to Demonstrate the Efficacy and Safety of ACT-293987 in Patients with Pulmonary Hypertension
04/01/2011 - 05/31/2017 (PI)
Actelion Pharmaceuticals, Ltd.

EPOCH Treatment Satisfaction Qualitative Study (EPOCH-TSQS)
03/10/2015 - 03/09/2017 (PI)
Actelion Pharmaceuticals, Ltd.

Showing 10 of 42 results. Show All Results

Title

Yr	Title	Project-Sub Proj	Pubs
2017	Dimethyl Fumarate In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension	1R21AR069285-01A1
2015	Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and	5P50AR060780-05-7133	80
2014	Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and	5P50AR060780-04-7133	80
2013	Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and	5P50AR060780-03-7133	80
2012	Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and	5P50AR060780-02-7133	80
2011	Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and	1P50AR060780-01-7133	80
2007	Oxidant State and Nitric Oxide Metabolism in the Acute Chest Syndrome	5U54HL070819-05-2	83
2006	Endothelial Cell Hypoxia Tolerance: Role of Plasmalogens	5R01HL068232-04	1
2006	Oxidant State and Nitric Oxide Metabolism in the Acute Chest Syndrome	5U54HL070819-04-2	83
2005	Endothelial Cell Hypoxia Tolerance: Role of Plasmalogens	5R01HL068232-03	1

Showing 10 of 25 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis Copy PMIDs To Clipboard

Farber HW, McDermott S, Witkin AS, Kelly NP, Miloslavsky EM, Stone JR. Case 11-2018: A 48-Year-Old Woman with Recurrent Venous Thromboembolism and Pulmonary Artery Aneurysm. N Engl J Med. 2018 Apr 12; 378(15):1430-1438. PMID: 29641962

Farber HW, Benza RL. Risk Assessment Tools in Pulmonary Arterial Hypertension. Prognosis for Prospective Trials? Am J Respir Crit Care Med. 2018 04 01; 197(7):843-845. PMID: 29373796

Farber HW, Badesch DB, Benza RL, Elliott CG, Frantz RP, McGoon MD, Selej M, Zhao C, Frost AE. Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL. J Heart Lung Transplant. 2018 08; 37(8):948-955. PMID: 29653800

Benza RL, Farber HW, Frost A, Grünig E, Hoeper MM, Busse D, Meier C, Nikkho S, Ghofrani HA. REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. J Heart Lung Transplant. 2018 07; 37(7):836-843. PMID: 29580746

Frantz RP, Farber HW, Badesch DB, Elliott CG, Frost AE, McGoon MD, Zhao C, Mink DR, Selej M, Benza RL. Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry. Chest. 2018 07; 154(1):126-135. PMID: 29355551

Abston E, Farber H. Pulmonary Cavity From Mycobacterium malmoense in an HIV-Infected Patient: Complicated by Bronchopleural Fistula. Open Forum Infect Dis. 2018 Feb; 5(2):ofy023. PMID: 29450215

Miller DP, Farber HW. Pulmonary Veno-Occlusive Disease: Welcome to the PAHty (Bostonian for Party). Circulation. 2017 11 21; 136(21):2034-2036. PMID: 29158214

Benza RL, Farber HW, Frost A, Ghofrani HA, Gómez-Sánchez MA, Langleben D, Rosenkranz S, Busse D, Meier C, Nikkho S, Hoeper MM. REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. J Heart Lung Transplant. 2018 04; 37(4):513-519. PMID: 29223470

Chakinala MM, Coyne DW, Benza RL, Frost AE, McGoon MD, Hartline BK, Frantz RP, Selej M, Zhao C, Mink DR, Farber HW. Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. J Heart Lung Transplant. 2018 06; 37(6):696-705. PMID: 29174533

Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Rubin LJ. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. J Heart Lung Transplant. 2018 03; 37(3):401-408. PMID: 29096938

Showing 10 of 209 results. Show More

Benza RL, Farber HW, Selej M, Gomberg-Maitland M. Assessing risk in pulmonary arterial hypertension: what we know, what we don't. Eur Respir J. 2017 08; 50(2). PMID: 28775053

Raina A, Benza RL, Farber HW. Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series. Pulm Circ. 2017 Jul-Sep; 7(3):741-746. PMID: 28671485

Taroni JN, Greene CS, Martyanov V, Wood TA, Christmann RB, Farber HW, Lafyatis RA, Denton CP, Hinchcliff ME, Pioli PA, Mahoney JM, Whitfield ML. A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis. Genome Med. 2017 Mar 23; 9(1):27.View Related Profiles.

Farber, Harrison
Lafyatis, Robert

PMID: 28330499; PMCID: PMC5363043; DOI: 10.1186/s13073-017-0417-1;

Farber HW, Gin-Sing W. Practical considerations for therapies targeting the prostacyclin pathway. Eur Respir Rev. 2016 Dec; 25(142):418-430. PMID: 27903664; DOI: 10.1183/16000617.0083-2016;

Sardana M, Moll M, Farber HW. Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension. Expert Opin Drug Metab Toxicol. 2016 Dec; 12(12):1513-1520. PMID: 27756196

Preston IR, Farber HW. Anti-coagulation in pulmonary arterial hypertension: the real blood and guts. J Thorac Dis. 2016 Sep; 8(9):E1106-E1107. PMID: 27747077

Finch KT, Stratton EA, Farber HW. Ranolazine for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction: A pilot study. J Heart Lung Transplant. 2016 11; 35(11):1370-1373. PMID: 27623099; DOI: 10.1016/j.healun.2016.07.015;

Cheong FY, Gower AC, Farber HW. Changes in gene expression profiles in patients with pulmonary arterial hypertension associated with scleroderma treated with tadalafil. Semin Arthritis Rheum. 2017 Feb; 46(4):465-472.View Related Profiles.

Gower, Adam
Farber, Harrison

PMID: 27499522; DOI: 10.1016/j.semarthrit.2016.05.015;

Preston IR, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW, Hill NS, Farber HW. Response to Letter Regarding Article, "Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)". Circulation. 2016 May 17; 133(20):e662. PMID: 27185031; DOI: 10.1161/CIRCULATIONAHA.116.022321;

Lenna S, Assassi S, Farina GA, Mantero JC, Scorza R, Lafyatis R, Farber HW, Trojanowska M. The HLA-B*35 allele modulates ER stress, inflammation and proliferation in PBMCs from Limited Cutaneous Systemic Sclerosis patients. Arthritis Res Ther. 2015; 17:363.View Related Profiles.

Farina, Giuseppina
Farber, Harrison
Trojanowska, Maria
Lafyatis, Robert

PMID: 26669670; PMCID: PMC4704539; DOI: 10.1186/s13075-015-0881-1;

Moll M, Payne JG, Tukey MH, Farber HW. Gestational pulmonary arterial hypertension. Pulm Circ. 2015 Dec; 5(4):730-3. PMID: 26697182; DOI: 10.1086/683689;

Farber HW, Gibbs S. Under pressure: pulmonary hypertension associated with left heart disease. Eur Respir Rev. 2015 Dec; 24(138):665-73. PMID: 26621980; DOI: 10.1183/16000617.0059-2015;

Waxman AB, Farber HW. Using Clinical Trial End Points to Risk Stratify Patients With Pulmonary Arterial Hypertension. Circulation. 2015 Dec 1; 132(22):2152-61. PMID: 26621638; DOI: 10.1161/CIRCULATIONAHA.114.012328;

Preston IR, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW, Hill NS, Farber HW. Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Circulation. 2015 Dec 22; 132(25):2403-11. PMID: 26510696; PMCID: PMC4689180; DOI: 10.1161/CIRCULATIONAHA.115.018435;

Sardana M, Moll M, Farber HW. Novel investigational therapies for treating pulmonary arterial hypertension. Expert Opin Investig Drugs. 2015; 24(12):1571-96. PMID: 26484967; DOI: 10.1517/13543784.2015.1098616;

Shah NP, Wallis N, Farber HW, Mauro MJ, Wolf RA, Mattei D, Guha M, Rea D, Peacock A. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol. 2015 Nov; 90(11):1060-4. PMID: 26284693; DOI: 10.1002/ajh.24174;

Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E, Romero AJ, Benton WW, Elliott CG, McGoon MD, Benza RL. Five-Year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015 Oct; 148(4):1043-54. PMID: 26066077; DOI: 10.1378/chest.15-0300;

Henriques-Forsythe M, Annangi S, Farber HW. Prevalence and hospital discharge status of human immunodeficiency virus-associated pulmonary arterial hypertension in the United States. Pulm Circ. 2015 Sep; 5(3):506-12. PMID: 26401251; DOI: 10.1086/682222;

Hill NS, Badesch D, Benza RL, D'Eletto TA, Farber HW, Gomberg-Maitland M, Hassoun PM, Preston I. Reply: Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration. Ann Am Thorac Soc. 2015 Jun; 12(6):960. PMID: 26075562; DOI: 10.1513/AnnalsATS.201505-263LE;

Sitbon O, Benza RL, Badesch DB, Barst RJ, Elliott CG, Gressin V, Lemarié JC, Miller DP, Muros-Le Rouzic E, Simonneau G, Frost AE, Farber HW, Humbert M, McGoon MD. Validation of two predictive models for survival in pulmonary arterial hypertension. Eur Respir J. 2015 Jul; 46(1):152-64. PMID: 25837032; DOI: 10.1183/09031936.00004414;

Grossman NL, Fiack CA, Weinberg JM, Rybin DV, Farber HW. Pulmonary hypertension associated with heart failure with preserved ejection fraction: acute hemodynamic effects of inhaled iloprost. Pulm Circ. 2015 Mar; 5(1):198-203.View Related Profiles.

Farber, Harrison
Weinberg, Janice

PMID: 25992282; PMCID: PMC4405721; DOI: 10.1086/679725;

Verla T, Marky A, Farber H, Petraglia FW, Gallis J, Lokhnygina Y, Parente B, Hickey P, Turner DA, Lad SP. Impact of advancing age on post-operative complications of deep brain stimulation surgery for essential tremor. J Clin Neurosci. 2015 May; 22(5):872-6. PMID: 25669119; PMCID: PMC4512238; DOI: 10.1016/j.jocn.2014.11.005;

Frantz RP, Schilz RJ, Chakinala MM, Badesch DB, Frost AE, McLaughlin VV, Barst RJ, Rosenberg DM, Miller DP, Hartline BK, Benton WW, Farber HW. Hospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational study. Chest. 2015 Feb; 147(2):484-94. PMID: 25320967; PMCID: PMC4314821; DOI: 10.1378/chest.14-1004;

Hill NS, Badesch D, Benza RL, D'Eletto TA, Farber HW, Gomberg-Maitland M, Hassoun PM, Preston I. Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration. Ann Am Thorac Soc. 2015 Feb; 12(2):269-73. PMID: 25590376; DOI: 10.1513/AnnalsATS.201501-020AS;

Chung L, Farber HW, Benza R, Miller DP, Parsons L, Hassoun PM, McGoon M, Nicolls MR, Zamanian RT. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest. 2014 Dec; 146(6):1494-504. PMID: 24992469; PMCID: PMC4251613; DOI: 10.1378/chest.13-3014;

Bradford MA, Farber HW. Are we correctly defining intermediate-risk pulmonary embolism? Chest. 2014 Nov; 146(5):e169. PMID: 25367487; DOI: 10.1378/chest.14-1362;

Hellawell JL, Bhattacharya S, Farber HW. Pharmacokinetic evaluation of treprostinil (oral) for the treatment of pulmonary arterial hypertension. Expert Opin Drug Metab Toxicol. 2014 Oct; 10(10):1445-53. PMID: 25204984; DOI: 10.1517/17425255.2014.958466;

Gopal DM, Doldt B, Finch K, Simms RW, Farber HW, Gokce N. Relation of novel echocardiographic measures to invasive hemodynamic assessment in scleroderma-associated pulmonary arterial hypertension. Arthritis Care Res (Hoboken). 2014 Sep; 66(9):1386-94.View Related Profiles.

Gopal, Deepa
Farber, Harrison
Gokce, Noyan
Simms, Robert

PMID: 24515598; PMCID: PMC4204737; DOI: 10.1002/acr.22307;

Farber HW, Miller DP, McGoon MD, Frost AE, Benton WW, Benza RL. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. J Heart Lung Transplant. 2015 Mar; 34(3):362-8. PMID: 25312386; DOI: 10.1016/j.healun.2014.08.020;

Farber HW, Miller DP. Cause of death in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2014 Feb; 33(2):222. PMID: 24365766; DOI: 10.1016/j.healun.2013.10.025;

Machado RF, Farber HW. Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders. Clin Chest Med. 2013 Dec; 34(4):739-52. PMID: 24267302; PMCID: PMC3916937; DOI: 10.1016/j.ccm.2013.08.006;

Miller DP, Farber HW. "Who'll be the next in line?" The lung allocation score in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2013 Dec; 32(12):1165-7. PMID: 24210050; DOI: 10.1016/j.healun.2013.10.004;

Farber HW, Miller DP, Meltzer LA, McGoon MD. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. J Heart Lung Transplant. 2013 Nov; 32(11):1114-22. PMID: 24035189; DOI: 10.1016/j.healun.2013.08.010;

Sadoughi A, Roberts KE, Preston IR, Lai GP, McCollister DH, Farber HW, Hill NS. Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension. Chest. 2013 Aug; 144(2):531-41. PMID: 23558791; DOI: 10.1378/chest.12-2081;

Poms AD, Turner M, Farber HW, Meltzer LA, McGoon MD. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. Chest. 2013 Jul; 144(1):169-76. PMID: 23348820; DOI: 10.1378/chest.11-3241;

Lenna S, Farina AG, Martyanov V, Christmann RB, Wood TA, Farber HW, Scorza R, Whitfield ML, Lafyatis R, Trojanowska M. Increased expression of endoplasmic reticulum stress and unfolded protein response genes in peripheral blood mononuclear cells from patients with limited cutaneous systemic sclerosis and pulmonary arterial hypertension. Arthritis Rheum. 2013 May; 65(5):1357-66.View Related Profiles.

Farber, Harrison
Trojanowska, Maria
Lafyatis, Robert
Christmann de Souza, Romy

PMID: 23400395; PMCID: PMC3636187; DOI: 10.1002/art.37891;

Esch JJ, Shah PB, Cockrill BA, Farber HW, Landzberg MJ, Mehra MR, Mullen MP, Opotowsky AR, Waxman AB, Lock JE, Marshall AC. Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: initial clinical experience. J Heart Lung Transplant. 2013 Apr; 32(4):381-7. PMID: 23415728; DOI: 10.1016/j.healun.2013.01.1049;

Frost AE, Farber HW, Barst RJ, Miller DP, Elliott CG, McGoon MD. Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry. Chest. 2013 Jan; 143(1):185-95. PMID: 22661451

Skondra D, Chang GC, Farber HW, Eliott D. Ophthalmologic diagnosis of exacerbation of idiopathic pulmonary arterial hypertension. Arch Ophthalmol. 2012 Dec; 130(12):1619-21. PMID: 23229713; DOI: 10.1001/archophthalmol.2012.1802;

Kitterman N, Poms A, Miller DP, Lombardi S, Farber HW, Barst RJ. Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY®. Mayo Clin Proc. 2012 Sep; 87(9):825-34. PMID: 22883740; PMCID: PMC3498408; DOI: 10.1016/j.mayocp.2012.05.014;

Farber HW. Validation of the 6-minute walk in patients with pulmonary arterial hypertension: trying to fit a square PEG into a round hole? Circulation. 2012 Jul 17; 126(3):258-60. PMID: 22696078; DOI: 10.1161/CIRCULATIONAHA.112.118547;

Farber HW. Pulmonary arterial hypertension in patients with HIV infection. European Respiratory Monograph. 2012; 57:82-93.

Schilz R, Farber HW. Quality initiatives and models of care in patients with pulmonary arterial hypertension: the time has come! Int J Clin Pract Suppl. 2011 Dec; (174):1-3. PMID: 22171815; DOI: 10.1111/j.1742-1241.2011.02835.x;

York M, Farber HW. Pulmonary hypertension: screening and evaluation in scleroderma. Curr Opin Rheumatol. 2011 Nov; 23(6):536-44.View Related Profiles.

Farber, Harrison
York, Michael

PMID: 21934501; DOI: 10.1097/BOR.0b013e32834ba6a7;

Badesch DB, Feldman J, Keogh A, Mathier MA, Oudiz RJ, Shapiro S, Farber HW, McGoon M, Frost A, Allard M, Despain D, Dufton C, Rubin LJ. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther. 2012 Apr; 30(2):93-9. PMID: 21884013; DOI: 10.1111/j.1755-5922.2011.00279.x;

Christmann RB, Hayes E, Pendergrass S, Padilla C, Farina G, Affandi AJ, Whitfield ML, Farber HW, Lafyatis R. Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension. Arthritis Rheum. 2011 Jun; 63(6):1718-28.View Related Profiles.

Farina, Giuseppina
Farber, Harrison
Lafyatis, Robert
Christmann de Souza, Romy

PMID: 21425123; PMCID: PMC4030759; DOI: 10.1002/art.30318;

Brown LM, Chen H, Halpern S, Taichman D, McGoon MD, Farber HW, Frost AE, Liou TG, Turner M, Feldkircher K, Miller DP, Elliott CG. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest. 2011 Jul; 140(1):19-26. PMID: 21393391; PMCID: PMC3198486; DOI: 10.1378/chest.10-1166;

Farber HW, Foreman AJ, Miller DP, McGoon MD. REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. Congest Heart Fail. 2011 Mar-Apr; 17(2):56-64. PMID: 21449993; DOI: 10.1111/j.1751-7133.2010.00202.x;

Walkey AJ, Fein D, Horbowicz KJ, Farber HW. Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension. Pulm Pharmacol Ther. 2011 Aug; 24(4):421-5.View Related Profiles.

Walkey, Allan
Farber, Harrison
Horbowicz, Kevin

PMID: 21251994; DOI: 10.1016/j.pupt.2011.01.002;

Lazar HL, Farber HW. Acute pulmonary embolism. N Engl J Med. 2010 Nov 11; 363(20):1974; author reply 1974-5.View Related Profiles.

Lazar, Harold
Farber, Harrison

PMID: 21067400; DOI: 10.1056/NEJMc1009061#SA6;

Pendergrass SA, Hayes E, Farina G, Lemaire R, Farber HW, Whitfield ML, Lafyatis R. Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS One. 2010; 5(8):e12106.View Related Profiles.

Farina, Giuseppina
Farber, Harrison
Lafyatis, Robert

PMID: 20808962; PMCID: PMC2923145; DOI: 10.1371/journal.pone.0012106;

Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, Krichman A, Liou TG, Raskob GE, Wason P, Feldkircher K, Turner M, McGoon MD. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2011 Jan; 139(1):128-37. PMID: 20558556; DOI: 10.1378/chest.10-0075;

Walkey AJ, Ieong M, Alikhan M, Farber HW. Cardiopulmonary exercise testing with right-heart catheterization in patients with systemic sclerosis. J Rheumatol. 2010 Sep; 37(9):1871-7.View Related Profiles.

Walkey, Allan
Farber, Harrison
Ieong, Michael
Alikhan, Mir

PMID: 20551099; DOI: 10.3899/jrheum.091424;

Farber HW, Simms RW, Lafyatis R. Care of patients with scleroderma in the intensive care setting. J Intensive Care Med. 2010 Sep; 25(5):247-58.View Related Profiles.

Farber, Harrison
Lafyatis, Robert
Simms, Robert

PMID: 20542965; DOI: 10.1177/0885066610371181;

Farber HW, Walkey AJ, O'Donnell MR. Ethical issues associated with globalization of placebo-controlled in pulmonary arterial hypertension. J Heart Lung Transplant. 2010 Jul; 29(7):825-6.View Related Profiles.

Walkey, Allan
Farber, Harrison

PMID: 20456982; DOI: 10.1016/j.healun.2010.03.010;

Hardy H, Backman ES, Farber HW. Successful bosentan and nonnucleoside reverse transcriptase inhibitor-based therapy in a patient with acquired immunodeficiency syndrome and pulmonary arterial hypertension. Pharmacotherapy. 2010 Apr; 30(4):139e-44e. PMID: 20334465; DOI: 10.1592/phco.30.4.422;

Lazar HL, Farber HW. Early pulmonary embolectomy for acute pulmonary embolus: an operation whose time has come. J Card Surg. 2010 May; 25(3):259-60.View Related Profiles.

Lazar, Harold
Farber, Harrison

PMID: 20202028; DOI: 10.1111/j.1540-8191.2010.01012.x;

Farber HW, Walkey AJ, Alikhan MM. The role of aldosterone in pulmonary venous hypertension. Chest. 2010 Feb; 137(2):502; author reply 502.View Related Profiles.

Walkey, Allan
Farber, Harrison

PMID: 20133311; DOI: 10.1378/chest.09-1864;

Fiack CA, Farber HW. Pulmonary hypertension associated with left ventricular diastolic dysfunction. J Heart Lung Transplant. 2010 Feb; 29(2):230-1. PMID: 20113913; DOI: 10.1016/j.healun.2009.07.014;

Walkey AJ, Farber HW, O'Donnell C, Cabral H, Eagan JS, Philippides GJ. The accuracy of the central venous blood gas for acid-base monitoring. J Intensive Care Med. 2010 Mar-Apr; 25(2):104-10.View Related Profiles.

Walkey, Allan
Philippides, George
Farber, Harrison
Cabral, Howard

PMID: 20018607; DOI: 10.1177/0885066609356164;

Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon MD. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010 Feb; 137(2):376-87. PMID: 19837821; DOI: 10.1378/chest.09-1140;

Summer R, Fiack CA, Ikeda Y, Sato K, Dwyer D, Ouchi N, Fine A, Farber HW, Walsh K. Adiponectin deficiency: a model of pulmonary hypertension associated with pulmonary vascular disease. Am J Physiol Lung Cell Mol Physiol. 2009 Sep; 297(3):L432-8.View Related Profiles.

Fine, Alan
Farber, Harrison
Walsh, Kenneth
Summer, Ross

PMID: 19561137; PMCID: PMC2739777; DOI: 10.1152/ajplung.90599.2008;

McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009 Apr 28; 53(17):1573-619. PMID: 19389575; DOI: 10.1016/j.jacc.2009.01.004;

Oudiz RJ, Farber HW. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J. 2009 Apr; 157(4):625-35. PMID: 19332188; DOI: 10.1016/j.ahj.2008.10.029;

McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009 Apr 28; 119(16):2250-94.View Related Profiles.

Jacobs, Alice
Farber, Harrison

PMID: 19332472; DOI: 10.1161/CIRCULATIONAHA.109.192230;

Safaya S, Klings ES, Odhiambo A, Li G, Farber HW, Steinberg MH. Effect of sodium butyrate on lung vascular TNFSF15 (TL1A) expression: differential expression patterns in pulmonary artery and microvascular endothelial cells. Cytokine. 2009 Apr; 46(1):72-8.View Related Profiles.

Klings, Elizabeth
Farber, Harrison
Steinberg, Martin

PMID: 19251437; PMCID: PMC2702851; DOI: 10.1016/j.cyto.2008.12.013;

Petcu, EB, Berman L, Opris MM, Gheorghiu V, Kessler SC, Hayes J, Farber HW. Pulmonary hypertension in systemic lupus erythematosus complicated by exposure to dexfenfluramine. Rom J Leg Med. 2009; 17:83-88.

Wilson KC, Farber HW. Propylene glycol accumulation during continuous-infusion lorazepam in critically ill patients. J Intensive Care Med. 2008 Nov-Dec; 23(6):413; author reply 414-5.View Related Profiles.

Farber, Harrison
Wilson, Kevin

PMID: 19019841; DOI: 10.1177/0885066608324175;

McGoon MD, Krichman A, Farber HW, Barst RJ, Raskob GE, Liou TG, Miller DP, Feldkircher K, Giles S. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc. 2008 Aug; 83(8):923-31. PMID: 18674477; DOI: 10.4065/83.8.923;

Klings ES, Anton Bland D, Rosenman D, Princeton S, Odhiambo A, Li G, Bernard SA, Steinberg MH, Farber HW. Pulmonary arterial hypertension and left-sided heart disease in sickle cell disease: clinical characteristics and association with soluble adhesion molecule expression. Am J Hematol. 2008 Jul; 83(7):547-53.View Related Profiles.

Klings, Elizabeth
Farber, Harrison
Steinberg, Martin
Bernard, Sheilah

PMID: 18383329; DOI: 10.1002/ajh.21187;

Distler O, Behrens F, Pittrow D, Huscher D, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Furst DE. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. Arthritis Rheum. 2008 Jun 15; 59(6):867-75. PMID: 18512721; DOI: 10.1002/art.23718;

Farber HW. The status of pulmonary arterial hypertension in 2008. Circulation. 2008 Jun 10; 117(23):2966-8. PMID: 18541751; DOI: 10.1161/CIRCULATIONAHA.108.782979;

Gaposchkin DP, Farber HW, Zoeller RA. On the importance of plasmalogen status in stimulated arachidonic acid release in the macrophage cell line RAW 264.7. Biochim Biophys Acta. 2008 Apr; 1781(4):213-9.View Related Profiles.

Farber, Harrison
Zoeller, Raphael

PMID: 18328831; DOI: 10.1016/j.bbalip.2008.01.007;

Fisher KA, Hill NS, Farber HW. Pathophysiology of Pulmonary Arterial Hypertension. In Pulmonary Hypertension (NS Hill & HW Farber, eds). Humana Press. Totowa, NJ. 2008; 145-172.
Farber HW. Pathophysiology of Pulmonary Arterial Hypertension. In Pulmonary Hypertension (NS Hill & HW Farber, eds). Humana Press. Totowa, NJ. 2008; 51-72.
Miller NS, Dobre MC, Liebschutz JM, Williams TC, Orr BL, Farber HW. Clinical Microbiology Newsletter. Micrococcus Bacteremia in a Patient with Pulmonary Hypertension and a Long-term Central Venous Catheter: Opportunity Knocks, and an Unexpected Pathogen Enters. 2007; 29(22):173-175.

Odhiambo A, Perlman DH, Huang H, Costello CE, Farber HW, Steinberg MH, McComb ME, Klings ES. Identification of oxidative post-translational modification of serum albumin in patients with idiopathic pulmonary arterial hypertension and pulmonary hypertension of sickle cell anemia. Rapid Commun Mass Spectrom. 2007; 21(14):2195-203.View Related Profiles.

Costello, Catherine
Klings, Elizabeth
Farber, Harrison
McComb, Mark
Steinberg, Martin

PMID: 17569101

Steiner MK, Preston IR, Klinger JR, Criner GJ, Waxman AB, Farber HW, Hill NS. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study. Chest. 2006 Nov; 130(5):1471-80. PMID: 17099026

Fisher KA, Serlin DM, Wilson KC, Walter RE, Berman JS, Farber HW. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest. 2006 Nov; 130(5):1481-8.View Related Profiles.

Farber, Harrison
Berman, Jeffrey
Wilson, Kevin

PMID: 17099027

Fiack CA, Farber HW. Heart failure with preserved ejection fraction. N Engl J Med. 2006 Oct 26; 355(17):1828; author reply 1830-1. PMID: 17065647

Patterson KC, Weissmann A, Ahmadi T, Farber HW. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med. 2006 Jul 18; 145(2):152-3. PMID: 16847299

Tam DH, Farber HW. Pulmonary hypertension and beta-thalassemia major: report of a case, its treatment, and a review of the literature. Am J Hematol. 2006 Jun; 81(6):443-7. PMID: 16680745

Klinger JR, Thaker S, Houtchens J, Preston IR, Hill NS, Farber HW. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest. 2006 Feb; 129(2):417-25. PMID: 16478861

Ieong MH, Farber HW. Non-infectious pulmonary complications of HIV infection. Clin Pulm Med. 2006; 13:194-202.

Zheng H, Duclos RI, Smith CC, Farber HW, Zoeller RA. Synthesis and biological properties of the fluorescent ether lipid precursor 1-O-[9'-(1'-pyrenyl)]nonyl-sn-glycerol. J Lipid Res. 2006 Mar; 47(3):633-42.View Related Profiles.

Farber, Harrison
Zoeller, Raphael

PMID: 16369049

Klinger JR, Houtchens J, Thaker S, Hill NS, Farber H. Acute cardiopulmonary hemodynamic effects of brain natriuretic peptide in patients with pulmonary arterial hypertension. Chest. 2005 Dec; 128(6 Suppl):618S-619S. PMID: 16373873

Preston IR, Klinger JR, Houtches J, Nelson D, Farber HW, Hill NS. Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. Respir Med. 2005 Dec; 99(12):1501-10. PMID: 15890512

Wilson KC, Reardon C, Theodore AC, Farber HW. Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational pilot study. Chest. 2005 Sep; 128(3):1674-81.View Related Profiles.

Theodore, Arthur
Reardon, Christine
Farber, Harrison
Wilson, Kevin

PMID: 16162774

Adewoye AH, Klings ES, Farber HW, Palaima E, Bausero MA, McMahon L, Odhiambo A, Surinder S, Yoder M, Steinberg MH, Asea A. Sickle cell vaso-occlusive crisis induces the release of circulating serum heat shock protein-70. Am J Hematol. 2005 Mar; 78(3):240-2.View Related Profiles.

Klings, Elizabeth
Farber, Harrison
Yoder, Mark
Steinberg, Martin

PMID: 15726596; PMCID: PMC1762099; DOI: 10.1002/ajh.20292;

Klings ES, Safaya S, Adewoye AH, Odhiambo A, Frampton G, Lenburg M, Gerry N, Sebastiani P, Steinberg MH, Farber HW. Differential gene expression in pulmonary artery endothelial cells exposed to sickle cell plasma. Physiol Genomics. 2005 May 11; 21(3):293-8.View Related Profiles.

Klings, Elizabeth
Farber, Harrison
Lenburg, Marc
Steinberg, Martin
Sebastiani, Paola

PMID: 15741505

Farber HW, Loscalzo J. Mechanism of disease: Pulmonary hypertension. Discov Med. 2005 Feb; 5(25):80-7. PMID: 20704929

Steinberg MH, Farber HW. Sickle Cell Disease. In Hospital Medicine (RM Wachter, L Goldman & H Hollander, eds). Lippincott Williams & Wilkins. Philadelphia. 2005; 965-974.

Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004 Oct 14; 351(16):1655-65. PMID: 15483284

Klings ES, Farber HW. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004 Jun 10; 350(24):2521-2; author reply 2521-2.View Related Profiles.

Klings, Elizabeth
Farber, Harrison

PMID: 15190149

Wilson KC, Bielska B, Farber HW. Mycobacterium marinum osteomyelitis. Orthopedics. 2003 Mar; 26(3):331-2.View Related Profiles.

Farber, Harrison
Wilson, Kevin

PMID: 12650330

Burkart KM, Farber HW. HIV-associated pulmonary hypertension: diagnosis and treatment. Adv Cardiol. 2003; 40:197-207. PMID: 14533555

Klings ES, Farber HW. The pathogenesis of HIV-associated pulmonary hypertension. Adv Cardiol. 2003; 40:71-82.View Related Profiles.

Klings, Elizabeth
Farber, Harrison

PMID: 14533547

Klings ES, Farber HW. The Pathogenesis of HIV-associated Pulmonary Hypertension. In HIV infection and the Cardiovascular System (G. Barbaro, editor). Karger. Basel. 2003; 71-82.
Farber HW. Pulmonary Hypertension. In the Merck Manual (M.H. Beers, ed). 2003; 322-325.
Burkart, K, Farber HW. HIV-associated Pulmonary Hypertension: Diagnosis and Treatment. In HIV infection and the Cardiovascular System (G. Barbaro, editor). Karger. Basel. 2003; 197-207.

Zoeller RA, Grazia TJ, LaCamera P, Park J, Gaposchkin DP, Farber HW. Increasing plasmalogen levels protects human endothelial cells during hypoxia. Am J Physiol Heart Circ Physiol. 2002 Aug; 283(2):H671-9.View Related Profiles.

Farber, Harrison
Lacamera, Peter
Zoeller, Raphael

PMID: 12124215

Jones H, Aguila E, Farber HW. Gabapentin toxicity requiring intubation in a patient receiving long-term hemodialysis. Ann Intern Med. 2002 Jul 2; 137(1):74. PMID: 12093261

Graven KK, Molvar C, Roncarati JS, Klahn BD, Lowrey S, Farber HW. Identification of protein disulfide isomerase as an endothelial hypoxic stress protein. Am J Physiol Lung Cell Mol Physiol. 2002 May; 282(5):L996-1003. PMID: 11943664

Forgione MA, Weiss N, Heydrick S, Cap A, Klings ES, Bierl C, Eberhardt RT, Farber HW, Loscalzo J. Cellular glutathione peroxidase deficiency and endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2002 Apr; 282(4):H1255-61.View Related Profiles.

Klings, Elizabeth
Farber, Harrison
Eberhardt, Robert
Heydrick, Stanley

PMID: 11893559

Hoeper MM, Galié N, Murali S, Olschewski H, Rubenfire M, Robbins IM, Farber HW, McLaughlin V, Shapiro S, Pepke-Zaba J, Winkler J, Ewert R, Opitz C, Westerkamp V, Vachiéry JL, Torbicki A, Behr J, Barst RJ. Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002 Feb 1; 165(3):341-4. PMID: 11818318

Wittram C, Fogg J, Farber H. Immune restoration syndrome manifested by pulmonary sarcoidosis. AJR Am J Roentgenol. 2001 Dec; 177(6):1427. PMID: 11717100

Klings ES, Christman BW, McClung J, Stucchi AF, McMahon L, Brauer M, Farber HW. Increased F2 isoprostanes in the acute chest syndrome of sickle cell disease as a marker of oxidative stress. Am J Respir Crit Care Med. 2001 Oct 1; 164(7):1248-52.View Related Profiles.

Stucchi, Arthur
Klings, Elizabeth
Farber, Harrison

PMID: 11673218

Klings ES, Farber HW. Role of free radicals in the pathogenesis of acute chest syndrome in sickle cell disease. Respir Res. 2001; 2(5):280-5.View Related Profiles.

Klings, Elizabeth
Farber, Harrison

PMID: 11686897; PMCID: PMC59517

Healy AM, Schwartz JJ, Zhu X, Herrick BE, Varnum B, Farber HW. Gas 6 promotes Axl-mediated survival in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2001 Jun; 280(6):L1273-81. PMID: 11350808

Farber HW. HIV-associated pulmonary hypertension. AIDS Clin Care. 2001 Jun; 13(6):53-5, 59. PMID: 11710309

Strohmeier GR, Walsh JH, Klings ES, Farber HW, Cruikshank WW, Center DM, Fenton MJ. Lipopolysaccharide binding protein potentiates airway reactivity in a murine model of allergic asthma. J Immunol. 2001 Feb 1; 166(3):2063-70.View Related Profiles.

Center, David
Klings, Elizabeth
Farber, Harrison
Cruikshank, William

PMID: 11160257

Klings ES, Farber HW. Current management of primary pulmonary hypertension. Drugs. 2001; 61(13):1945-56.View Related Profiles.

Klings, Elizabeth
Farber, Harrison

PMID: 11708765

Scarfo LM, Weller PF, Farber HW. Induction of endothelial cell cytoplasmic lipid bodies during hypoxia. Am J Physiol Heart Circ Physiol. 2001 Jan; 280(1):H294-301. PMID: 11123244

Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med. 2000 Nov; 162(5):1846-50. PMID: 11069824

Healy AM, Morgenthau L, Zhu X, Farber HW, Cardoso WV. VEGF is deposited in the subepithelial matrix at the leading edge of branching airways and stimulates neovascularization in the murine embryonic lung. Dev Dyn. 2000 Nov; 219(3):341-52.View Related Profiles.

Farber, Harrison
Cardoso, Wellington

PMID: 11066091

Wilson KC, Reardon C, Farber HW. Propylene glycol toxicity in a patient receiving intravenous diazepam. N Engl J Med. 2000 Sep 14; 343(11):815.View Related Profiles.

Farber, Harrison
Wilson, Kevin

PMID: 10991709

Klings ES, Farber HW. IV epoprostenol for systemic sclerosis. Chest. 2000 Sep; 118(3):881-2.View Related Profiles.

Klings, Elizabeth
Farber, Harrison

PMID: 10988225

Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Trolliet M, Heydrick S, Stark R, Klings ES, Moldovan NI, Yaghoubi M, Goldschmidt-Clermont PJ, Farber HW, Cohen R, Loscalzo J. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest. 2000 Aug; 106(4):483-91.View Related Profiles.

Klings, Elizabeth
Farber, Harrison
Stark, Rachel
Cohen, Richard
Eberhardt, Robert
Heydrick, Stanley

PMID: 10953023; PMCID: PMC380245

Klings ES, Farber HW. Epoprostenol for pulmonary hypertension in scleroderma. Ann Intern Med. 2000 Jul 18; 133(2):158.View Related Profiles.

Klings, Elizabeth
Farber, Harrison

PMID: 10896643

Hendra KP, Farber HW. Foreign body granulomatosis. In Internal Medicine Pearls (Heffner JE, Sahn SA, eds). Hanley & Belfus, Inc. Philadelphia. 2000; 228-230.

Panchenko MV, Farber HW, Korn JH. Induction of heme oxygenase-1 by hypoxia and free radicals in human dermal fibroblasts. Am J Physiol Cell Physiol. 2000 Jan; 278(1):C92-C101.View Related Profiles.

Farber, Harrison
Panchenko, Maria

PMID: 10644516

Klings ES, Hill NS, Ieong MH, Simms RW, Korn JH, Farber HW. Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin). Arthritis Rheum. 1999 Dec; 42(12):2638-45.View Related Profiles.

Klings, Elizabeth
Farber, Harrison
Ieong, Michael
Simms, Robert

PMID: 10616012

Farber HW, Loscalzo J. Prothrombotic mechanisms in primary pulmonary hypertension. J Lab Clin Med. 1999 Dec; 134(6):561-6. PMID: 10595782

Graven KK, Yu Q, Pan D, Roncarati JS, Farber HW. Identification of an oxygen responsive enhancer element in the glyceraldehyde-3-phosphate dehydrogenase gene. Biochim Biophys Acta. 1999 Oct 28; 1447(2-3):208-18. PMID: 10542317

Hammerman SI, Klings ES, Hendra KP, Upchurch GR, Rishikof DC, Loscalzo J, Farber HW. Endothelial cell nitric oxide production in acute chest syndrome. Am J Physiol. 1999 Oct; 277(4 Pt 2):H1579-92.View Related Profiles.

Rishikof, David
Klings, Elizabeth
Farber, Harrison

PMID: 10516198

Keaveny AP, Karasik MS, Farber HW. Successful treatment of chylous ascites secondary to Mycobacterium avium complex in a patient with the acquired immune deficiency syndrome. Am J Gastroenterol. 1999 Jun; 94(6):1689-90. PMID: 10364047

Farber HW, Graven KK, Kokolski G, Korn JH. Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma. J Rheumatol. 1999 May; 26(5):1195-6. PMID: 10332990

Graven KK, Farber HW. Endothelial cell hypoxic stress proteins. J Lab Clin Med. 1998 Dec; 132(6):456-63. PMID: 9851734

Farber HW, Graven KK. Endothelial cell hypoxic stress proteins. Chest. 1998 Jul; 114(1 Suppl):64S-65S. PMID: 9676633

Tucci M, Nygard K, Tanswell BV, Farber HW, Hill DJ, Han VK. Modulation of insulin-like growth factor (IGF) and IGF binding protein biosynthesis by hypoxia in cultured vascular endothelial cells. J Endocrinol. 1998 Apr; 157(1):13-24. PMID: 9614353

Graven KK, McDonald RJ, Farber HW. Hypoxic regulation of endothelial glyceraldehyde-3-phosphate dehydrogenase. Am J Physiol. 1998 Feb; 274(2 Pt 1):C347-55. PMID: 9486123

Rounds S, Piggott D, Dawicki DD, Farber HW. Effect of hypercarbia on surface proteins of cultured bovine endothelial cells. Am J Physiol. 1997 Dec; 273(6 Pt 1):L1141-6. PMID: 9435568

Crimlisk JT, Bernardo J, Blansfield JS, Loughlin M, McGonagle EG, McEachern G, Roeber J, Farber HW. Endotracheal reintubation: a closer look at a preventable condition. Clin Nurse Spec. 1997 Jul; 11(4):145-50; quiz 151-2.View Related Profiles.

Farber, Harrison
Bernardo, John

PMID: 9274152

Hammerman SI, Kourembanas S, Conca TJ, Tucci M, Brauer M, Farber HW. Endothelin-1 production during the acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med. 1997 Jul; 156(1):280-5. PMID: 9230761

Tucci M, Hammerman SI, Furfaro S, Saukonnen JJ, Conca TJ, Farber HW. Distinct effect of hypoxia on endothelial cell proliferation and cycling. Am J Physiol. 1997 May; 272(5 Pt 1):C1700-8. PMID: 9176162

Graven KK, Farber HW. Endothelial hypoxic stress proteins. Kidney Int. 1997 Feb; 51(2):426-37. PMID: 9027717

Wagner RP, Farber HW. HIV-Related pulmonary problems. In A Practical Approach to Pulmonary Medicine (Goldstein RH, O'Connell JJ, Karlinsky JB, eds.). Lipincott-Raven. Philadelphia. 1997; 416-436.
Saukkonen JJ, Farber HW. Lymphocytic Interstitial Pneumonitis. In AIDS and Respiratory Medicine (Zumla A, Johnson MA, Miller RF, eds.). Chapman & Hall. London. 1997; 331-343.

Polesky A, Farber HW, Gottlieb DJ, Park H, Levinson S, O'Connell JJ, McInnis B, Nieves RL, Bernardo J. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med. 1996 Nov; 154(5):1473-7.View Related Profiles.

Farber, Harrison
O'Connell, James
Bernardo, John

PMID: 8912767

Tucci M, McDonald RJ, Aaronson R, Graven KK, Farber HW. Specificity and uniqueness of endothelial cell stress responses. Am J Physiol. 1996 Sep; 271(3 Pt 1):L341-8. PMID: 8843781

Farber HW, Barber TW. Mycobacterial infections. In HIV Infection: A Primary Care Manual (Libman H, Witzburg RA, eds.). Little, Brown and Co. Boston. 1996; 309-324.
Wagner RP, Farber HW. Pulmonary manifestations. In HIV Infection: A Primary Care Manual (Libman H, Witzburg RA, eds.). Little, Brown and Co. Boston. 1996; 139-163..

Aaronson RM, Graven KK, Tucci M, McDonald RJ, Farber HW. Non-neuronal enolase is an endothelial hypoxic stress protein. J Biol Chem. 1995 Nov 17; 270(46):27752-7. PMID: 7499243

Graven KK, Farber HW. Hypoxia-associated proteins. New Horiz. 1995 May; 3(2):208-18. PMID: 7583162

Farber HW. Long-term resolution of disseminated Mycobacterium avium complex infection in a patient with AIDS. Clin Infect Dis. 1995 Apr; 20(4):1067-8. PMID: 7795056

Tretyakov AV, Farber HW. Endothelial cell tolerance to hypoxia. Potential role of purine nucleotide phosphates. J Clin Invest. 1995 Feb; 95(2):738-44. PMID: 7860755; PMCID: PMC295542

Montgomery AB, Feigal DW, Jr., Sattler F, Mason GR, Catanzaro A, Edison R, Markowitz N, Johnson E, Ogawa S, Rovzar M, Udem SA, Eden E, Hyslop N, Cheung TW, Kessler H, Mildvan D, Giron JA, Ettinger N, Crumpacker C, Frame, P, Steigbigel N, van der Horst C, Hirsch M, Lederman MM, Hewitt RG, Fallat R, Farber HW, Sacks HS, Eisman SA, Luce JM, Boylan T, Adams M, Feinberg J,Hopewell PC. Pentamidine aerosolized versus trimethoprim-sulfamethoxazole for pneumocystis carinii in Acquired Immunodeficiency Syndrome. Am J Respir Crit Care Med. 1995; 151:1068-1074.

Crimlisk JT, Paris R, McGonagle EG, Calcutt JA, Farber HW. The closed tracheal suction system: implications for critical care nursing. Dimens Crit Care Nurs. 1994 Nov-Dec; 13(6):292-300. PMID: 7729318

Lee VW, Cooley TP, Fuller JD, Ward RJ, Farber HW. Pulmonary mycobacterial infections in AIDS: characteristic pattern of thallium and gallium scan mismatch. Radiology. 1994 Nov; 193(2):389-92.View Related Profiles.

Farber, Harrison
Fuller, Jon
Cooley, Timothy

PMID: 7972748

Graven KK, Troxler RF, Kornfeld H, Panchenko MV, Farber HW. Regulation of endothelial cell glyceraldehyde-3-phosphate dehydrogenase expression by hypoxia. J Biol Chem. 1994 Sep 30; 269(39):24446-53.View Related Profiles.

Farber, Harrison
Panchenko, Maria

PMID: 7929107

Katz MF, Farber HW, Dodds-Stitt Z, Cruikshank WW, Beer DJ. Serotonin-stimulated aortic endothelial cells secrete a novel T lymphocyte chemotactic and growth factor. J Leukoc Biol. 1994 May; 55(5):567-73.View Related Profiles.

Farber, Harrison
Cruikshank, William

PMID: 7514199

Katz MF, Beer DJ, Duquette D, Cruikshank WW, Antonov AS, Romanov YA, Smirnov VN, Farber HW. Secretion of a novel T-lymphocyte cytokine possessing both chemotactic and growth factor activity by serotonin-stimulated human aortic endothelial cells. Exp Cell Res. 1994 May; 212(1):113-9.View Related Profiles.

Farber, Harrison
Cruikshank, William

PMID: 8174633

Tarpy SP, Farber HW. Chronic lung disease: when to prescribe home oxygen. Geriatrics. 1994 Feb; 49(2):27-8, 31-3. PMID: 8307386

Graven KK, Zimmerman LH, Dickson EW, Weinhouse GL, Farber HW. Endothelial cell hypoxia associated proteins are cell and stress specific. J Cell Physiol. 1993 Dec; 157(3):544-54. PMID: 8253866

Weinhouse GL, Belloni PN, Farber HW. Effect of hypoxia on endothelial cell surface glycoprotein expression: modulation of glycoprotein IIIa and other specific surface glycoproteins. Exp Cell Res. 1993 Oct; 208(2):465-78. PMID: 8375475

Tretyakov AV, Farber HW. Endothelial cell phospholipid distribution and phospholipase activity during acute and chronic hypoxia. Am J Physiol. 1993 Sep; 265(3 Pt 1):C770-80. PMID: 8214033

Beer DJ, Farber HW. Secretion profiles of vasoactive amine-induced leukocyte chemoattractants: Evidence for endothelial cell heterogeneity. Signal Transduction in Lung Cells (Brody JS, Center DM, Tkachuck V, eds). Marcel Dekker, Inc. New York. 1993; 435-457.
Wagner RP, Farber HW. Pulmonary manifestations. In Clinical Manual of HIV Infection (Libman H, Witzburg RA, eds.). Little, Brown and Co. Boston. 1993; 124-145.
Farber HW, Barber TW. Mycobacterial infections. In Clinical Manual of HIV Infection (Libman H, Witzburg RA, eds.). Little, Brown and Co. Boston. 1993; 263-274.

Karlinsky JB, Rounds S, Farber HW. Effects of hypoxia on heparan sulfate in bovine aortic and pulmonary artery endothelial cells. Circ Res. 1992 Oct; 71(4):782-9.View Related Profiles.

Farber, Harrison
Karlinsky, Joel

PMID: 1516155

Montecalvo MA, Steger KA, Farber HW, Smith BF, Dennis RC, Fitzpatrick GF, Pollack SD, Korsberg TZ, Birkett DH, Hirsch EF, et al. Nutritional outcome and pneumonia in critical care patients randomized to gastric versus jejunal tube feedings. The Critical Care Research Team. Crit Care Med. 1992 Oct; 20(10):1377-87.View Related Profiles.

Farber, Harrison
Pollack, Sidney

PMID: 1395657

Farber HW, Antonov AS, Romanov YA, Smirnov VN, Scarfo LM, Beer DJ. Cytokine secretion by human aortic endothelial cells is related to degree of atherosclerosis. Am J Physiol. 1992 Apr; 262(4 Pt 2):H1088-95. PMID: 1566891

Simms RW, Zerbini CAF, Ferrante N, Anthony J, Felson DT, Craven DE and the Boston City Hospital Clinical AIDS Team (Chen J, Chapman SE, Cooley TP, Fuller JD, Libman H, Lebow J, Fagan M, Farber HW, Martin M, Steger KA, Zeeman BA). Fibromyalgia syndrome in patients infected with human immunodeficiency virus. Am J Med. 1992; 92:368-374.

Farber HW, Kozlova M, Moldobalva A, Charles A, Danilov SM. Production of neutrophil-specific lipid chemoattractant activity by cultured endothelial cells: heterogeneity dependent on species, ligand, or endothelial cell site of origin. Tissue Cell. 1992; 24(3):355-66. PMID: 1636173

Hill NS, Jacoby C, Farber HW. Effect of an endurance triathlon on pulmonary function. Med Sci Sports Exerc. 1991 Nov; 23(11):1260-4. PMID: 1766341

Barber TW, Craven DE, Farber HW. Mycobacterium gordonae: a possible opportunistic respiratory tract pathogen in patients with advanced human immunodeficiency virus, type 1 infection. Chest. 1991 Sep; 100(3):716-20. PMID: 1889262

Farber HW, Beer DJ. Restricted secretion of a T-lymphocyte chemotactic cytokine by serotonin-stimulated cultured aortic endothelial cells. Circ Res. 1991 Aug; 69(2):257-65. PMID: 1860174

Charles A, Rounds S, Farber HW. Neutrophil chemoattractant production by cultured serotonin-stimulated bovine and human endothelial cells. Am J Physiol. 1991 Aug; 261(2 Pt 1):L133-9. PMID: 1872407

Farber HW, Schaefer EJ, Franey R, Grimaldi R, Hill NS. The endurance triathlon: metabolic changes after each event and during recovery. Med Sci Sports Exerc. 1991 Aug; 23(8):959-65. PMID: 1956272

Villanueva AG, Farber HW, Rounds S, Goldstein RH. Stimulation of fibroblast collagen and total protein formation by an endothelial cell-derived factor. Circ Res. 1991 Jul; 69(1):134-41.View Related Profiles.

Farber, Harrison
Goldstein, Ronald

PMID: 2054930

Farber HW, Barnett HF. Differences in prostaglandin metabolism in cultured aortic and pulmonary arterial endothelial cells exposed to acute and chronic hypoxia. Circ Res. 1991 May; 68(5):1446-57. PMID: 1902149

Zimmerman LH, Levine RA, Farber HW. Hypoxia induces a specific set of stress proteins in cultured endothelial cells. J Clin Invest. 1991 Mar; 87(3):908-14. PMID: 1999500; PMCID: PMC329881

Farber HW. Differences in pulmonary and systemic arterial endothelial cell adaptation to chronic hypoxia. In Response and Adaptation to Hypoxia - Organ to Organelle (Lahiri S, Cherniak NS, Fitzgerald RS, eds). Oxford University Press. New York. 1991; 195-201.

Saitz R, Williams BW, Farber HW. Atenolol-induced cardiovascular collapse treated with hemodialysis. Crit Care Med. 1991 Jan; 19(1):116-8.View Related Profiles.

Farber, Harrison
Saitz, Richard

PMID: 1986875

Farber HW, Rounds S. Effect of long-term hypoxia on cultured aortic and pulmonary arterial endothelial cells. Exp Cell Res. 1990 Nov; 191(1):27-36. PMID: 2226649

Farber HW, Center DM, Rounds S, Danilov SM. Components of the angiotensin system cause release of a neutrophil chemoattractant from cultured bovine and human endothelial cells. Eur Heart J. 1990 Apr; 11 Suppl B:100-7.View Related Profiles.

Center, David
Farber, Harrison

PMID: 2194806

Farber HW, Fairman RP, Rounds S, Millan JE, Glauser FL. Pulmonary hypertensive response to foreign body microemboli. Prostaglandins Leukot Essent Fatty Acids. 1990 Feb; 39(2):151-7. PMID: 2111555

Farber HW, Marks EJ. Case records of the Massachusetts General Hospital (Case 1-1990). N Engl J Med. 1990; 322:43-52.

Lamon-Fava S, McNamara JR, Farber HW, Hill NS, Schaefer EJ. Acute changes in lipid, lipoprotein, apolipoprotein, and low-density lipoprotein particle size after an endurance triathlon. Metabolism. 1989 Sep; 38(9):921-5. PMID: 2505019

Farber HW, Fairman RP, Millan JE, Rounds S, Glauser FL. Pulmonary response to foreign body microemboli in dogs: release of neutrophil chemoattractant activity by vascular endothelial cells. Am J Respir Cell Mol Biol. 1989 Jul; 1(1):27-35. PMID: 2624757

Benditt JO, Farber HW, Wright J, Karnad AB. Pulmonary hemorrhage with diffuse alveolar infiltrates in men with high-volume choriocarcinoma. Ann Intern Med. 1988 Oct 15; 109(8):674-5. PMID: 2458694

Rounds S, Farber HW, Render ML, Barnard FA. Effects of hypoxia and hypercarbia on cultured endothelial cells. Chest. 1988 Mar; 93(3 Suppl):156S-157S. PMID: 3342697

Driks MR, Craven DE, Celli BR, Manning M, Burke RA, Garvin GM, Kunches LM, Farber HW, Wedel SA, McCabe WR. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. The role of gastric colonization. N Engl J Med. 1987 Nov 26; 317(22):1376-82. PMID: 2891032

Farber HW, Center DM, Rounds S. Effect of ambient oxygen on cultured endothelial cells from different vascular beds. Am J Physiol. 1987 Oct; 253(4 Pt 2):H878-83.View Related Profiles.

Center, David
Farber, Harrison

PMID: 3661737

Farber HW, Laguarda R. Human pulmonary dirofilarial infection. Ann Intern Med. 1987 May; 106(5):777-8. PMID: 3565986

Villanueva AG, Farber HW. Pulmonary complications in AIDS patients. Curr Rev Respir Crit Care. 1987; 9:127-132.
Farber HW, Arbetter J, Schaefer EJ, Hill SP, Dallal G, Grimaldi R, Hill NS. Acute metabolic effects of an endurance triathlon. Ann Sports Med. 1987; 3:131-138.

Farber HW, Weller PF, Rounds S, Beer DJ, Center DM. Generation of, lipid neutrophil chemoattractant activity by histamine-stimulated cultured endothelial cells. J Immunol. 1986 Nov 1; 137(9):2918-24.View Related Profiles.

Center, David
Farber, Harrison

PMID: 3760577

Farber HW. Long-term oxygen therapy in COPD. Am Rev Respir Dis. 1986 Jan; 133(1):173. PMID: 3942372

Farber HW, Center DM, Rounds S. Bovine and human endothelial cell production of neutrophil chemoattractant activity in response to components of the angiotensin system. Circ Res. 1985 Dec; 57(6):898-902.View Related Profiles.

Center, David
Farber, Harrison

PMID: 3905045

Rounds S, Farber HW, Hill NS, O'Brien RF. Effects of endothelial cell injury on pulmonary vascular reactivity. Chest. 1985 Oct; 88(4 Suppl):213S-216S. PMID: 3930163

Farber HW, Make B. Physiologic closure of a symptomatic patent foramen ovale with oxygen therapy. Am Rev Respir Dis. 1985 Jan; 131(1):181-3. PMID: 3966707

Farber HW, Karlinsky JB, Faling LJ. Fatal outcome following nifedipine for pulmonary hypertension. Chest. 1983 Apr; 83(4):708-9.View Related Profiles.

Farber, Harrison
Karlinsky, Joel
Faling, Leendert

PMID: 6831965

Farber H, Glauser FL. The effect of oral hydralazine on the pulmonary hemodynamics of patients with pulmonary foreign body granulomatosis. Chest. 1982 Dec; 82(6):708-12. PMID: 7140398

Farber HW, Fairman RP, Glauser FL. Talc granulomatosis: laboratory findings similar to sarcoidosis. Am Rev Respir Dis. 1982 Feb; 125(2):258-61. PMID: 6278999

Farber HW, Falls R, Glauser FL. Transient pulmonary hypertension from the intravenous injection of crushed, suspended pentazocine tablets. Chest. 1981 Aug; 80(2):178-82. PMID: 7249763

Farber HA, Tucker HS, Jasnosz KM. Morbidity and mortality conference: thrombotic thrombocytopenic purpura. Va Med. 1981 Jun; 108(6):405-9. PMID: 7195635

Farber HW, Kerkering TM, Jasnosz KM. Morbidity and mortality conference: acute pulmonary blastomycosis. Va Med. 1981 Mar; 108(3):177-82. PMID: 7223000

Farber HW, Mathers JA, Glauser FL. Gallium scans and serum angiotensin converting enzyme levels in talc granulomatosis and lymphocytic interstitial pneumonitis. South Med J. 1980 Dec; 73(12):1663-7. PMID: 6255609

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 24 publications over 16 distinct years, with a maximum of 3 publications in 1993 and 2003

Bar chart showing 24 publications over 16 distinct years, with a maximum of 3 publications in 1993 and 2003

Year	Publications
1987	2
1990	1
1991	1
1992	1
1993	3
1995	1
1996	2
1997	2
2000	1
2003	3
2005	1
2006	1
2007	1
2008	2
2009	1
2012	1

Media Mentions

Improved Pulmonary Arterial Hypertension Risk Prediction Tools Needed

The Cardiology Advisor 5/28/2018

Contact for Mentoring:

Media Mentions

The Cardiology Advisor